April 3rd-4th Dr. Pourhassan attended the technical meeting arranged by flow cytometry world leader BD Biosciences. It was a valuable meeting with multiple great presentations and networking with peers.
April 4th our CEO attended the partnering meeting in Lund, arranged by Medicon Village and Life Science Sweden. It was a great day with networking and multiple meetings on establishing collaborative initiatives with several of the other participants. We are pretty excited about this and are currently working on framing these collaborations with partners. We […]
Our CEO has been invited as an expert speaker to this year’s Next Gen IO congress, to be held in London March 14.-15. Dr. Frøsig will talk about the need for doing proper immune monitoring and about our established assay for Deep Profiling of Antigen-Specific T cells and our strategy for offering a TCR safety […]
Based on customer requests and the position of ELISPOT (enzyme-linked immunospot) as the most often used method for detection of antigen-specific T cells we are happy to now offer our expertise within this method for our clients. Find more information at the ELISPOT site.
We are in the process of re-designing our homepage. We are happy to have taken the first step by publishing a handful of new pages about our efforts within detection of antigen-specific T cells populations using intracellular cytokine staining, ELISPOT (new), common MHC multimer staining and our unique dCODE Dextramer platform for simultaneous detection of […]
We are delighted to be included in the March issue of the Pharma Technology Focus magazine in two sections: https://pharma.nridigital.com/pharma_mar19/immumap and https://pharma.nridigital.com/pharma_mar19/immumap_company_insight Take a look at our part of the magazine as well as the remaining content – it looks really good.
We are proud to announce that the T Cell Receptor fingerprinting platform developed by our co-founder Professor Sine Reker Hadrup and her group has just been published in Nature Biotechnology (DOI. 10.1038/nbt.4303). We believe this platform as a one-pot strategy for determining the interactions governing the affinity between the peptide-MHC complex and the T Cell […]
ImmuMap, a state-of-the-art flow cytometry services company, is entering into a collaboration with the innovative Norwegian company, Zelluna Immunotherapy, working on cutting-edge cellular immunotherapies based on T cell receptor technologies. We have already performed several studies together, including a large flow cytometry-based investigation of several of Zelluna’s T cell receptors. These studies will support the development of Zelluna’s […]
We look forward to attending the Bio-Agora Summit at University of Copenhagen. Focus for this years Summit is Immuno-oncology, with esteemed IO Biotech CEO Mai-Britt Zocca and immune-oncology pioneering chief physician and director of the Center for Cancer Immune Therapy Professor Inge Marie Svane as speakers. We look forward to participating in interesting IO discussions […]
As per today our site at Drug Development Technology is public! We are pleased to have been chosen by the people behind Drug Development Technology and look forward to having increased customer flow due to our presence also on this platform. Drug Development Technology represents leading companies within all aspects of life science. https://www.drugdevelopment-technology.com/contractors/contract_research/immumap/
We are happy to have our press release included in the Greater Copenhagen Life Science Magazine November issue focused on the BIO-Europe partnering conference. http://nemmedia.dk/copenhagen-life-science/
We unfortunately had an email accounts breakdown in the period from August 10th to August 13th. We are now up and running again, but are not able to see any emails sent in this period, so please resend any important messages and we will get back to you as soon as we can
We at ImmuMap, a state-of-the-art flow cytometry services company, have performed a robustness study investigating reliability of our flow cytometry analyses for a T cell lineage marker panel. We are confident with the results; please visit https://immumap.com/single-cell-analysis/ for information about our single cell analyses and for downloading our one-pager.
ImmuMap, a state-of-the-art flow cytometry services company, will participate in this year’s Danish IP Fair at “Industriens Hus”, inner Copenhagen, showcasing inventions from all Danish Universities and being a nice venue for networking with both small and large companies. Please drop by our booth for a chat.
March 8. ImmuMap CEO Thomas M. Frøsig was invited to share his view and experience on pursuing a research-based career within the biotech industry and as a business co-founder. More than 100 high school students were actively listening and asking questions. The “Day of Research” also included visits at some of the bigger companies located […]
ImmuMap, a state-of-the-art flow cytometry services company, participated in the annual Medico Bazar at the DTU for showcasing our services, networking and one-to-one meetings with potential clients and collaboration partners.
CEO of ImmuMap Thomas M. Frøsig has been invited to present our view on in vitro mechanism-of-action analyses at the Biologics Symposium for Immuno-Oncology products organized by the very large contract-research organization (CRO) ENVIGO. We look forward to participate in an exciting symposium! The symposium will be held twice, Tuesday 16 January in Copenhagen and […]
ImmuMap Services, a state-of-the-art flow cytometry services company, is proud to announce collaboration with Vaccibody, a leading cancer vaccine development company based in Oslo, Norway. We are currently using multicolor flow cytometry to investigate the in vivo efficacy of Vaccibody’s personalized neoantigen cancer vaccine. We will continue testing samples for multiple antigen-specific T cell responses […]
ImmuMap Services, a state-of-the-art flow cytometry services company, is proud to announce the initiation of a long-term collaboration with pharma company Materia Medica Holding per September 6th 2017 and currently until the end of 2020. We are at present investigating several compounds supplied by Materia Medica Holding to reveal their mechanism-of-action upon stimulation of human […]
September 21st ImmuMap CEO Thomas M. Frøsig was invited as a speaker at the “Studieretningernes dag” at Høje Taastrup High School to inspire and inform first-year students about a carrier in health science. ImmuMap is happy to this way be able to take on social responsibility.
ImmuMap is happy to announce results from this year’s MHC multimer proficiency panel testing. 18 experienced immune monitoring laboratories from 10 countries participated, and ImmuMap did well in a comparable analysis with an overall maximal proficiency score. For further details see http://www.immudex.com/media/58254/immudex-report-mhc-multimer-proficiency-panel-2017.pdf and look for lab ID 516. The MHC multimer proficiency panel initiative was […]
We look forward to attending the Biomarker AGORA 2017 at University of Copenhagen, Thorvaldsensvej 40 to get inspired and to network with peers and collaborators
ImmuMap CEO Thomas M. Frøsig and Scientific Advisor Sine Reker Hadrup will attend the CRI-CIMT-EATI-AACR international Cancer Immune Therapy Conference in Mainz, Germany, September 6th-9th. Please reach out at email@example.com or cell phone: +45 6178 1882 to arrange a non-committal meeting at the conference.
Happy to welcome new employee Senior Scientist Houman Pourhassan. Houman’s primary responsibility will be the laboratory work and we look forward to taking advantage of his expertise within both human and murine flow cytometry.
By April 1st ImmuMap Services moved to be part of the inspiring environment at Scion DTU in Lyngby. Here, we expect to further develop our company taking advantage of the business development and innovation professionals placed in-house.
In the February issue of Pharma Thomas M Frøsig is interviewed about the challenges of starting up a company and serving many roles at one time.
ImmuMap Services and CEO Thomas Mørch Frøsig featured in the article “DTU-spinout vil have fingrene i lukrativt kræftområde” (in Danish) published by Medwatch.dk. The article describes our vision as the company offering advanced immune analyses that provide the customers a more detailed understanding of mechanism-of-action for their drug candidates. http://medwatch.dk/secure/Medicinal___Biotek/article9237323.ece
ImmuMap Services ApS enter into service agreement with CytoVac A/S under which ImmuMap Services will perform immune monitoring of samples from CytoVac’s innovative ALECSAT therapy for undisclosed cancer targets. Home
ImmuMap Services featured in the article “Understanding how drugs actually work at the cellular level” published by BioPeople.dk, Denmark’s life science cluster. Here, Randi Krogsgaard nicely explains about our competencies and how we aim to accelerate immune therapy development by elucidating mechanisms-of-action. http://www.biopeople.dk/news-room/news-stories/news/?tx_ttnews%5Btt_news%5D=200&cHash=6d7e23fd9744bffb351f9e44988c8e40
As of November 1th, 2016 ImmuMap Services start providing immune assesment services, consultancy and training on a fee for service basis. Ultimo 2016 ImmuMap Services will be offering state-of-the-art high throughput MHC/peptide epitope mapping as contract research.
ImmuMap Services enter into close collaboration with Immudex on the use of state-of-the-art MHC Dextramers for single- and multiplex immune analyses of antigen-specific T cells.
ImmuMap Services participate in the Agora 2016 Biomarker workshop. http://www.bioagora.dk
Recently, founders of ImmuMap Services published their ground-breaking method for high-troughput T cell epitope discover. The publication featured online in high-impact Nature Biotechnology on August 29th, 2016.